Scarica l'app Stockscreener
4.16
3.93%
-0.17
Dopo l'orario di chiusura:
4.16
Precedente Chiudi:
$4.33
Aprire:
$4.22
Volume 24 ore:
4.67M
Relative Volume:
0.52
Capitalizzazione di mercato:
$324.71M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-1.3165
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
-27.15%
1M Prestazione:
-26.63%
6M Prestazione:
-62.35%
1 anno Prestazione:
-62.42%
Intervallo 1D:
$3.90
$4.31
Intervallo di 1 settimana:
$3.12
$4.4399
Portata 52W:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Confronta REPL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.16 | 337.98M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Investigation announced for Long-Term Investors in shares - openPR.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Strategies to average down on Replimune Group Inc.Market Movers & Technical Buy Zone Confirmation - newser.com
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - Morningstar
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
Tools to assess Replimune Group Inc.’s risk profilePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - GlobeNewswire Inc.
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - Stockhouse
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire Inc.
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
2025-09-20 | REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. InvestorsLead Plaintiff Deadline September 22, 2025 | NDAQ:REPL | Press Release - Stockhouse
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL | FinancialContent - FinancialContent
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action PendingHagens Berman - PR Newswire
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha
JPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Analyzing recovery setups for Replimune Group Inc. investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
Why Replimune Stock Was Tumbling Again Today - AOL.com
Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgrade - GuruFocus
Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty - GuruFocus
Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Insider Monkey
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
JP Morgan Downgrades Replimune Group (REPL) to Underweight | REP - GuruFocus
Replimune stock unchanged as H.C. Wainwright maintains Neutral rating - Investing.com
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire
Factset, Metlife, Replimune - TradingView
Replimune stock rating downgraded by JPMorgan on regulatory concerns - Investing.com
Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL - MarketBeat
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Why Replimune Stock Plummeted by Almost 40% Today - MSN
Replimune (REPL) Faces Setback After FDA Meeting - GuruFocus
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
REPLIMUNE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the FirmREPL - MarketScreener
Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire
Shareholders that lost money on Replimune Group, Inc. - GlobeNewswire
Replimune stock plunges after FDA meeting fails to clear path forward - Investing.com Australia
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):